ALTRENO Drug Patent Profile
✉ Email this page to a colleague
When do Altreno patents expire, and when can generic versions of Altreno launch?
Altreno is a drug marketed by Dow Pharm and is included in one NDA. There are two patents protecting this drug.
This drug has six patent family members in six countries.
The generic ingredient in ALTRENO is tretinoin. There are twenty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the tretinoin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Altreno
A generic version of ALTRENO was approved as tretinoin by PADAGIS US on December 24th, 1998.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ALTRENO?
- What are the global sales for ALTRENO?
- What is Average Wholesale Price for ALTRENO?
Summary for ALTRENO
| International Patents: | 6 |
| US Patents: | 2 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 141 |
| Clinical Trials: | 2 |
| Drug Prices: | Drug price information for ALTRENO |
| What excipients (inactive ingredients) are in ALTRENO? | ALTRENO excipients list |
| DailyMed Link: | ALTRENO at DailyMed |
Recent Clinical Trials for ALTRENO
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Beth Israel Deaconess Medical Center | Phase 4 |
| Ortho Dermatologics | Phase 4 |
| Bausch Health Americas, Inc. | Phase 4 |
Pharmacology for ALTRENO
| Drug Class | Retinoid |
US Patents and Regulatory Information for ALTRENO
ALTRENO is protected by two US patents.
Patents protecting ALTRENO
Topical pharmaceutical compositions for treating skin conditions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
Topical pharmaceutical compositions for treating skin conditions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TOPICAL TREATMENT OF ACNE VULGARIS IN PATIENTS 9 YEARS OF AGE AND OLDER
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dow Pharm | ALTRENO | tretinoin | LOTION;TOPICAL | 209353-001 | Aug 23, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Dow Pharm | ALTRENO | tretinoin | LOTION;TOPICAL | 209353-001 | Aug 23, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ALTRENO
International Patents for ALTRENO
See the table below for patents covering ALTRENO around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Poland | 213237 | ⤷ Sign Up | |
| China | 101305982 | ⤷ Sign Up | |
| Japan | 2004505900 | ⤷ Sign Up | |
| World Intellectual Property Organization (WIPO) | 0211683 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ALTRENO
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1304992 | 474 | Finland | ⤷ Sign Up | |
| 1304992 | 122013000081 | Germany | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCIN (ALS CLINDAMYCIN-PHOSPHAT) UND TRETINOIN; NAT. REGISTRATION NO/DATE: 85210.00.00 20130611; FIRST REGISTRATION: IRLAND PA1332/043/001 20130322 |
| 1304992 | CR 2013 00053 | Denmark | ⤷ Sign Up | PRODUCT NAME: CLINDAMYCIN (SOM CLINDAMYCIN PHOSPHATE) OG TRETINOIN; NAT. REG. NO/DATE: 48954 20130416; FIRST REG. NO/DATE: IE PA1332/043/001 20130322 |
| 1304992 | 132013902214376 | Italy | ⤷ Sign Up | PRODUCT NAME: CLINDAMICINA FOSFATO E TRETINOINA(ACNATAC); AUTHORISATION NUMBER(S) AND DATE(S): PA1332/043/001, 20130322;042056010/M - 022/M, 20130718 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
